研究者
J-GLOBAL ID:202001015721282019   更新日: 2024年02月01日

柴崎 晶彦

shibazaki masahiko
競争的資金等の研究課題 (10件):
  • 2021 - 2023 ヘムオキシゲナーゼを分子標的とした悪性黒色腫の浸潤転移抑制方法の確立
  • 2018 - 2021 悪性黒色腫の浸潤転移機構におけるNFE2L2の役割の解析
  • 2017 - 2020 中皮腫におけるHippo不活化で誘導されるヒアルアドヘリンの播種性転移機構の解明
  • 2013 - 2016 RhoGDI2の大腸癌転移機構への関与の検討
  • 2012 - 2015 新規LincRNAの腫瘍生物学的形質への関与
全件表示
論文 (39件):
  • Hirofumi Kamada, Shinji Yasuhira, Masahiko Shibazaki, Hiroo Amano, Chihaya Maesawa. DUSP4 Inactivation Leads to Reduced Extracellular Signal-Regulated Kinase Activity through Upregulation of DUSP6 in Melanoma Cells. Journal of Investigative Dermatology. 2022. 142. 9. 2499-2507.e6
  • Zhiqian Yu, Masahiro Shibazaki, Hirotada Otsuka, Haruhiko Takada, Masanori Nakamura, Yasuo Endo. Dynamics of Platelet Behaviors as Defenders and Guardians: Accumulations in Liver, Lung, and Spleen in Mice. Biological and Pharmaceutical Bulletin. 2019. 42. 8. 1253-1267
  • Masao Nishiya, Shinji Yasuhira, Masahiko Shibazaki, Hiroki Oikawa, Tomoyuki Masuda, Chihaya Maesawa. Fluvastatin exerts an antitumor effect in vemurafenib-resistant melanoma cells. Anti-Cancer Drugs. 2019. 30. 5. 451-457
  • Eri Saeki, Shinji Yasuhira, Masahiko Shibazaki, Hiroshi Tada, Minoru Doita, Tomoyuki Masuda, Chihaya Maesawa. Involvement of C-terminal truncation mutation of kinesin-5 in resistance to kinesin-5 inhibitor. PLOS ONE. 2018. 13. 12. e0209296-e0209296
  • Nobuyuki Arakawa, Ayaka Okubo, Shinji Yasuhira, Kazuhiro Takahashi, Hiroo Amano, Toshihide Akasaka, Tomoyuki Masuda, Masahiko Shibazaki, Chihaya Maesawa. Carnosic acid, an inducer of NAD(P)H quinone oxidoreductase 1, enhances the cytotoxicity of β-lapachone in melanoma cell lines. Oncology Letters. 2017
もっと見る
MISC (2件):
  • Sho Kakizawa, Masahiko Shibazaki, Nozomu Mori, Hiroshi Takeshima. Protein Oxidation Inhibits Nitric Oxide-Mediated Signaling Pathway Essential for Synaptic Plasticity. BIOPHYSICAL JOURNAL. 2011. 100. 3. 89-89
  • Naoko Izutsu, Chihaya Maesawa, Masahiko Shibazaki, Hiroki Oikawa, Tadahiro Shoji, Toru Sugiyama, Tomoyuk Masuda. Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells. INTERNATIONAL JOURNAL OF ONCOLOGY. 2008. 32. 6. 1227-1235
※ J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。 登録・更新については、こちらをご覧ください。

前のページに戻る